Browsing Tag
melioidosis
2 posts
AN2 Therapeutics reveals 40% 90-day mortality in NIH-backed melioidosis study, advancing epetraborole toward Phase 2 trial
AN2 Therapeutics reports high 90-day mortality in 200-patient NIH-funded melioidosis study, laying groundwork for Phase 2 epetraborole trial in 2025.
Idera Pharmaceuticals acquires rare orphan disease company Aceragen
Idera Pharmaceuticals, a US-based biopharma company, has acquired Aceragen, a biotechnology company focused on developing drugs for rare,…